aTyr Pharma, Inc. (LIFE)
| Previous Close | 1.7200 |
| Open | 1.7100 |
| Bid | 1.6700 x 400 |
| Ask | 1.7000 x 100 |
| Day's Range | 1.6690 - 1.7100 |
| 52 Week Range | 1.0800 - 2.7000 |
| Volume | |
| Avg. Volume | 563,583 |
| Market Cap | 116.718M |
| Beta (5Y Monthly) | 1.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9400 |
| Earnings Date | Aug 07, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.60 |
GlobeNewswireaTyr Pharma to Present at Upcoming Investor Conferences
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at several upcoming investor conferences scheduled to take place in May and June 2024. Details of the conferences appear below: Conference: RBC Capital Markets Glob
- GlobeNewswire
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment in the second quarter of 2024. Ended the first quarter 2024 with $87.7 million in cash, cash equivalents, restricted cash and investments. SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today
Simply Wall St.aTyr Pharma Insiders Placed Bullish Bets Worth US$514.6k
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
